Will the UK become a “desert for healthcare innovation”?
That is the claim made by the Association of the British Pharmaceutical Industry (ABPI). Lisa Anson, who took over as ABPI president last week, told The Times that the financial squeeze on the NHS threatened the whole of Britain’s £30 billion life sciences sector as firms would reconsider working in the UK. ABPI asked for the…